(SYK) Stryker - Ratings and Ratios
Implants, Navigation, Endoscopy, Spine, Orthobiologics
SYK EPS (Earnings per Share)
SYK Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 23.9% |
| Value at Risk 5%th | 34.7% |
| Reward | |
|---|---|
| Sharpe Ratio | -0.20 |
| Alpha Jensen | -15.63 |
| Character | |
|---|---|
| Hurst Exponent | 0.591 |
| Beta | 0.899 |
| Drawdowns 3y | |
|---|---|
| Max DD | 16.56% |
| Mean DD | 4.59% |
Description: SYK Stryker September 25, 2025
Stryker Corporation (NYSE: SYK) is a diversified medical-technology firm that operates two primary business segments: MedSurg & Neurotechnology and Orthopaedics. The MedSurg & Neurotechnology segment supplies a broad portfolio that includes surgical equipment, navigation and endoscopic systems, AI-enabled virtual-care platforms, acute-stroke minimally invasive devices, cranial and maxillofacial products, as well as orthobiologic materials such as synthetic bone grafts and vertebral-augmentation solutions. The Orthopaedics segment focuses on implants for total joint replacements (hip, knee, shoulder), trauma and extremities, plus thoracolumbar fixation and minimally invasive spinal systems.
The company distributes its products directly and through third-party dealers in roughly 75 countries, serving physicians, hospitals, and other healthcare facilities. Founded in 1941, Stryker is headquartered in Portage, Michigan, and has grown through both organic innovation and strategic acquisitions (e.g., the 2022 purchase of Wright Medical for $4.7 bn, expanding its trauma and extremities footprint).
Key performance indicators from the most recent FY 2023 filing show revenue of $21.0 bn (+6 % YoY), operating margin of 15.8 % (up from 14.9 % in FY 2022), and a 12-month trailing R&D spend of $1.9 bn (≈9 % of sales). The orthopaedic implant market is driven by an aging U.S. population and rising joint-replacement volumes, with the American Joint Replacement Registry estimating >1 million procedures annually-a secular tailwind that underpins Stryker’s growth outlook. However, the segment remains sensitive to reimbursement policy shifts and potential supply-chain disruptions in high-mix, low-volume surgical devices.
For a deeper quantitative assessment of Stryker’s valuation dynamics-including forward cash-flow models and peer-adjusted multiples-exploring the analytics on ValueRay can provide the granular data needed to refine your investment thesis.
SYK Stock Overview
| Market Cap in USD | 136,154m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 1988-02-01 |
| Return 12m vs S&P 500 | -16.1% |
| Analyst Rating | 4.06 of 5 |
SYK Dividends
| Dividend Yield | 0.92% |
| Yield on Cost 5y | 1.53% |
| Yield CAGR 5y | 8.30% |
| Payout Consistency | 96.5% |
| Payout Ratio | 25.5% |
SYK Growth Ratios
| CAGR | 19.26% |
| CAGR/Max DD Calmar Ratio | 1.16 |
| CAGR/Mean DD Pain Ratio | 4.20 |
| Current Volume | 2228k |
| Average Volume | 1489k |
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income (2.94b TTM) > 0 and > 6% of Revenue (6% = 1.46b TTM) |
| FCFTA 0.09 (>2.0%) and ΔFCFTA 1.34pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 25.83% (prev 31.87%; Δ -6.05pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.10 (>3.0%) and CFO 4.83b > Net Income 2.94b (YES >=105%, WARN >=100%) |
| Net Debt (13.34b) to EBITDA (4.66b) ratio: 2.86 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.85 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (386.7m) change vs 12m ago 0.29% (target <= -2.0% for YES) |
| Gross Margin 62.63% (prev 61.28%; Δ 1.36pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 53.65% (prev 50.13%; Δ 3.52pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 21.99 (EBITDA TTM 4.66b / Interest Expense TTM 159.0m) >= 6 (WARN >= 3) |
Altman Z'' 3.58
| (A) 0.13 = (Total Current Assets 13.71b - Total Current Liabilities 7.41b) / Total Assets 47.06b |
| (B) 0.42 = Retained Earnings (Balance) 19.96b / Total Assets 47.06b |
| (C) 0.08 = EBIT TTM 3.50b / Avg Total Assets 45.45b |
| (D) 0.76 = Book Value of Equity 19.23b / Total Liabilities 25.27b |
| Total Rating: 3.58 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 69.04
| 1. Piotroski 8.50pt = 3.50 |
| 2. FCF Yield 2.73% = 1.36 |
| 3. FCF Margin 16.71% = 4.18 |
| 4. Debt/Equity 0.76 = 2.22 |
| 5. Debt/Ebitda 2.86 = -1.56 |
| 6. ROIC - WACC (= -0.42)% = -0.53 |
| 7. RoE 13.92% = 1.16 |
| 8. Rev. Trend 81.84% = 6.14 |
| 9. EPS Trend 51.50% = 2.57 |
What is the price of SYK shares?
Over the past week, the price has changed by +0.30%, over one month by -0.33%, over three months by -3.22% and over the past year by -3.13%.
Is Stryker a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SYK is around 362.19 USD . This means that SYK is currently overvalued and has a potential downside of -0.42%.
Is SYK a buy, sell or hold?
- Strong Buy: 13
- Buy: 9
- Hold: 9
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the SYK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 428.5 | 17.8% |
| Analysts Target Price | 428.5 | 17.8% |
| ValueRay Target Price | 403.5 | 10.9% |
SYK Fundamental Data Overview November 09, 2025
P/E Trailing = 46.7231
P/E Forward = 24.3902
P/S = 5.5844
P/B = 6.6102
P/EG = 1.864
Beta = 0.899
Revenue TTM = 24.38b USD
EBIT TTM = 3.50b USD
EBITDA TTM = 4.66b USD
Long Term Debt = 12.19b USD (from longTermDebt, last fiscal year)
Short Term Debt = 1.75b USD (from shortTermDebt, last quarter)
Debt = 16.59b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 13.34b USD (from netDebt column, last quarter)
Enterprise Value = 149.41b USD (136.15b + Debt 16.59b - CCE 3.34b)
Interest Coverage Ratio = 21.99 (Ebit TTM 3.50b / Interest Expense TTM 159.0m)
FCF Yield = 2.73% (FCF TTM 4.07b / Enterprise Value 149.41b)
FCF Margin = 16.71% (FCF TTM 4.07b / Revenue TTM 24.38b)
Net Margin = 12.07% (Net Income TTM 2.94b / Revenue TTM 24.38b)
Gross Margin = 62.63% ((Revenue TTM 24.38b - Cost of Revenue TTM 9.11b) / Revenue TTM)
Gross Margin QoQ = 63.60% (prev 62.27%)
Tobins Q-Ratio = 3.18 (Enterprise Value 149.41b / Total Assets 47.06b)
Interest Expense / Debt = 0.96% (Interest Expense 159.0m / Debt 16.59b)
Taxrate = 16.52% (170.0m / 1.03b)
NOPAT = 2.92b (EBIT 3.50b * (1 - 16.52%))
Current Ratio = 1.85 (Total Current Assets 13.71b / Total Current Liabilities 7.41b)
Debt / Equity = 0.76 (Debt 16.59b / totalStockholderEquity, last quarter 21.79b)
Debt / EBITDA = 2.86 (Net Debt 13.34b / EBITDA 4.66b)
Debt / FCF = 3.27 (Net Debt 13.34b / FCF TTM 4.07b)
Total Stockholder Equity = 21.14b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.25% (Net Income 2.94b / Total Assets 47.06b)
RoE = 13.92% (Net Income TTM 2.94b / Total Stockholder Equity 21.14b)
RoCE = 10.49% (EBIT 3.50b / Capital Employed (Equity 21.14b + L.T.Debt 12.19b))
RoIC = 7.98% (NOPAT 2.92b / Invested Capital 36.57b)
WACC = 8.40% (E(136.15b)/V(152.75b) * Re(9.33%) + D(16.59b)/V(152.75b) * Rd(0.96%) * (1-Tc(0.17)))
Discount Rate = 9.33% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.36%
[DCF Debug] Terminal Value 77.37% ; FCFE base≈3.73b ; Y1≈4.60b ; Y5≈7.84b
Fair Price DCF = 276.0 (DCF Value 105.53b / Shares Outstanding 382.4m; 5y FCF grow 24.98% → 3.0% )
EPS Correlation: 51.50 | EPS CAGR: 2.26% | SUE: 0.99 | # QB: 5
Revenue Correlation: 81.84 | Revenue CAGR: 5.69% | SUE: 0.18 | # QB: 0
Additional Sources for SYK Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle